Search clinical trials for: bromfenac 0.09%

Total 2476 results

Melissa Toyos
Bausch & Lomb Incorporated

Completed

Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery (QD)

Inflammation | Cataract | Retinal Edema

United States
Pfizer

Completed

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Plaque Psoriasis | Atopic Dermatitis

United States, Canada, United Kingdom, Japan
Eisai Limited

Completed

A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
Bausch & Lomb Incorporated

Completed

Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease

Dry Eye Disease

United States
Innovative Medical

Completed

Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients

Cataract

United States
Babasaheb Ambedkar Memorial Hospital

Completed

Comparison of Treatments in Diabetic Macular Edema

Diabetic Macular Edema
Bucci Laser Vision Institute
Allergan

Completed

A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)

Post Operative Anterior Chamber Inflammation (Flare)

United States
Galderma R&D

Completed

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) (CTCL)

Cutaneous T Cell Lymphoma

United States, France, Germany
Spirig Pharma Ltd.

Completed

Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions

Actinic Keratosis

Switzerland, Germany
Allergan

Completed

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
SCAI Therapeutics

Completed

Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis

Dry Eye Syndromes

Korea, Republic of
Abramson Cancer Center of the University of Pennsylvania

Completed

Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)

Cutaneous T Cell Lymphoma

United States
Frank A. Bucci, Jr., M.D.
Allergan

Completed

A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification

Cataracts

United States
Sun Pharmaceutical Industries Limited

Completed

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Keratoconjunctivitis Sicca | Dry Eye Disease

United States
Wills Eye

Completed

Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.

Pain | Pain, Acute | Intravitreal Injection

United States, Canada
Hospital de La Luz

Unknown

Topical Bromfenac for Intraoperative Miosis and Pain Reduction

Cataract

Mexico
Toyos Clinic
Bausch & Lomb Incorporated

Completed

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%

Inflammation | Pseudophakia
Eisai Inc.

Completed

Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis

Chronic Plaque Psoriasis

United States
Bausch & Lomb Incorporated

Completed

A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease

Dry Eye Syndrome

United States
Cindy Hutnik
Glaucoma Research Society of Canada

Unknown

NSAID vs Steroid in Trabeculectomy Wound Management

Glaucoma
Arcispedale Santa Maria Nuova-IRCCS

Completed

Bromfenac Versus Dexamethasone After Cataract Surgery (BVD)

Inflammation Eye

Italy
Aerie Pharmaceuticals

Completed

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Ocular Hypertension | Open Angle Glaucoma

Japan
Utrecht Institute for Pharmaceutical Sciences

Completed

Effects of Alcohol on Simulated Driving

Alcoholism

Netherlands
AstraZeneca

Completed

Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Non-Insulin-Dependent

United States
SIFI SpA

Completed

Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects

Acanthamoeba Keratitis
Seoul National University Hospital

Recruiting

Bromfenac Sodium Hydrate Eye Drops in Familial Exudative Vitreoretinopathy

Familial Exudative Vitreoretinopathies

Korea, Republic of
Johns Hopkins University

Withdrawn

Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.

Cystoid Macular Edema

United States
Allergan

Completed

A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction

Meibomian Gland Dysfunction

United States
Aerie Pharmaceuticals

Completed

Study of AR-13324 in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Kyungpook National University Hospital

Completed

Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification

Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification
Università degli Studi di Brescia

Completed

NSAIDs and PGE2 Levels in Vitrectomy Patients

Vitreous Inflammation
Bp Consulting, Inc

Completed

Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)

Intraocular Pressure

United States
Laboratorios Sophia S.A de C.V.

Completed

Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo. (PRO-155/IV)

Ocular Inflammation | Ocular Pain | Pterygium | Post-surgical Inflammation

Mexico
Bausch & Lomb Incorporated

Completed

Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery

Pain | Inflammation | Cataract

United States
Bausch & Lomb Incorporated

Completed

Efficacy and Safety of Bromfenac Ophthalmic Solution

Cataract Surgery

United States
Ophthalmic Consultants of Boston
Bausch & Lomb Incorporated

Unknown

Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser

Diabetic Macular Edema

United States
Bausch & Lomb Incorporated

Completed

Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery

Pain | Inflammation

United States
Bausch & Lomb Incorporated

Completed

Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery

Cataract

United States
Allergan

Completed

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Spain, France, Belgium, Israel, United Kingdom, Poland, Italy, Czechia, Germany, Hungary
Bausch & Lomb Incorporated

Completed

Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery

Pain | Inflammation

United States
Klinički Bolnički Centar Zagreb
University of Zagreb

Completed

PCME Prevention in Patients With NPDR

Cystoid Macular Edema Following Cataract Surgery

Croatia
Cairo University

Not yet recruiting

Effect of Apical Enlargement to Different Preparation Sizes and Tapers on Pain and Bacterial Reduction in Necrotic Pulp

Necrotic Pulp
University of Trieste

Completed

PGE2 Levels in Patient Treated With NSAIDs

Ocular Inflammation

Italy
Sun Yat-sen University
Ministry of Health, China

Completed

Topical 0.1% Bromfenac Sodium and Prostaglandin E2 Inhibition in Cataract Surgery

Cataract

China
Bp Consulting, Inc

Completed

Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.

Diabetic Macular Edema

United States
Florida Eye Microsurgical Institute
Bausch & Lomb Incorporated

Completed

Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase

Dry Eye Disease | Ocular Comfort

United States
Allergan

Completed

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Jinyang Li

Completed

Evaluation of Therapeutic Effect of Bandage Contact Lenses ( BCL) on Dry Eye Caused by Sjogren's Syndrome (BCL)

Sjögren's Syndrome Patients With Severe Dry Eye

China
Innovative Medical

Completed

Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%

Vitrectomy

United States
Oregon Health and Science University
Genentech, Inc.

Completed

Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration

Age-Related Macular Degeneration

United States

3

Subscribe